Dear ASN Members:
I would like to share some exciting newASNeuro stats 2020s and updates about ASN NEURO, our society journal. First and foremost, the 2019 2-year Impact Factor from Clarivate was just released, and was determined to be 4.167, which represents a 54% increase from the previous year. The numbers of submissions, papers published, and citations for 2019 papers makes it promising that the impact factor will remain the same or higher for 2020. One of the driving forces of high impact factors are review articles that attract readers and citations. Two new special collections “Special Collection on Celebrating 50 Years of GFAP” and “Special Collection on Therapeutic Potential of Extracellular Vesicles in Neurological Damage and Disease”, are now open for submissions, and major review articles will appear there shortly.
A new section has been added to the website entitled “Editor's Choice" which will highlight recent articles. Current highlights cover two recent reviews “Shedding Light on the Dark Side of the Microglia” and “NRF2 as a Therapeutic Target in Neurodegenerative Diseases”, an original article describing selective neuronal loss in AD mouse models “Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer’s Disease”, and a commentary on therapeutic approaches for Alzheimer’s disease "Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle”.
ASN Officers and Council want to thank all the ASN members who have contributed to the success of our journal, and hope you will continue to read, recommend, and submit manuscripts. Remember that ASN members receive 50% discount on all page charges.
Douglas Feinstein, Editor-in-Chief ASNeuro